impact factor
logo
 

2001 Vol.19, N°6 - Suppl.25 - Table of contents

Controversies in COX-2 inhibitor therapy

Guest Editors: S.B. Abramson, D.E. Furst, M.C. Hochberg, C. Patrono

Full Papers

CER1973
2001,19,6,Suppl.25
Pg. 0003-0008

Free to view

The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint
R.W. Moskowitz

Rheumatology Abstract

Rheumatology Article

 

CER1974
2001,19,6,Suppl.25
Pg. 0009-0014

Free to view

The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint
M. Dougados

Rheumatology Abstract

Rheumatology Article

11th International Congress on Systemic Lupus Erythematosus

CER1975
2001,19,6,Suppl.25
Pg. 0015-0022

Free to view

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective
M.C. Hochberg

Rheumatology Abstract

Rheumatology Article

Full Papers

CER1976
2001,19,6,Suppl.25
Pg. 0023-0030

Free to view

NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials ? The gastroenterologist's perspective
C.J. Hawkey

Rheumatology Abstract

Rheumatology Article

 

CER1977
2001,19,6,Suppl.25
Pg. 0031-0036

Free to view

COX-2 inhibitors and the cardiovascular system
G.A. FitzGerald, Y. Cheng, S. Austin

Rheumatology Abstract

Rheumatology Article

 

CER1978
2001,19,6,Suppl.25
Pg. 0037-0040

Free to view

COX-2 inhibitors and the kidney
G.B. Appel

Rheumatology Abstract

Rheumatology Article

 

CER1979
2001,19,6,Suppl.25
Pg. 0041-0044

Free to view

The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data
L.A. Garcia Rodriguez

Rheumatology Abstract

Rheumatology Article

 

CER1980
2001,19,6,Suppl.25
Pg. 0045-0050

Free to view

Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity
C. Patrono

Rheumatology Abstract

Rheumatology Article

 

CER1981
2001,19,6,Suppl.25
Pg. 0051-0057

Free to view

Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective
K. Brune, A. Neubert

Rheumatology Abstract

Rheumatology Article

 

CER1982
2001,19,6,Suppl.25
Pg. 0059-0062

Free to view

Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspective
R.O. Day

Rheumatology Abstract

Rheumatology Article

 

CER1983
2001,19,6,Suppl.25
Pg. 0063-0070

Free to view

Analgesia and COX-2 inhibition
R.A. Dionne, A.A. Khan, S.M. Gordon

Rheumatology Abstract

Rheumatology Article

 

CER1984
2001,19,6,Suppl.25
Pg. 0071-0076

Free to view

Future directions in pain management
D.E. Furst, D.C. Manning

Rheumatology Abstract

Rheumatology Article